The answer to this is very simple. Have a company present a drug or treatment that slows the decline or improves the functioning of AD patients that does not attack AD via amyloid. So far the FDA hasn't seen such a drug or treatment. I wonder what company will be the first to do that?
B. How does FDA unscrew itself from Amyloid thesis CNS disease past w/a straight face and move on?
News 
Market Data 
Discover 
